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In 1962, an antibody to a high-prevalence antigen
was described by Schmidt et al.1 and named anti-Sm.
The following year, Anderson et al.2 described an
antibody to a low-prevalence antigen and named it anti-
Bua. These antigens were determined at that time to be
independent of ABO, MNS, P, Lewis, Rh, Kell, Kidd, and
Duffy blood group systems. In a study by Lewis et al.3
in 1964, a hypothesis on the possible antithetical
relationship between the antigens Sm and Bua was
proposed. In 1967, Lewis et al.4 presented further
evidence supporting the hypothesis of this antithetical
relationship and Sm and Bua were indeed determined
to be products of allelic genes. Sm and Bua
subsequently were shown to be genetically
independent of other blood group loci and renamed
Sc1 and Sc2,respectively.5 The blood group system was
named Scianna (SC), after the initial propositus. This
conventional terminology shall be used henceforth in
this review.
McCreary et al.6 first described an antibody present
in the serum of a patient from the Marshall Islands
(Micronesia) with an apparent Sc:–1,–2 phenotype,
which reacted with all RBCs tested except her own
and those of her cousin with the same apparent
Sc:–1,–2 phenotype. These findings suggested yet
another antigen of high prevalence within the Scianna
blood group system. These findings were substantiated
when Nason et al.7 discovered an antibody in the
serum of a Caucasian man that reacted with all RBCs
except his own and those of the two before-mentioned
Sc:–1,–2 Micronesians. Adsorption and elution studies
failed to reveal the presence of separable anti-Sc1 or
anti-Sc2; therefore, the antibody was named anti-Sc3
and the corresponding antigen was named Sc3.
In 1967, Rausen et al.8 described an antibody to a
low-prevalence antigen present in five women who
delivered children with HDN with detectable antibody
on their cord RBCs. The antigen and corresponding
antibody were named Rd and anti-Rd, respectively, after
the Radin family in which they were first discovered.
At that time, the Rd antigen was believed to be
independent of any other blood group loci. In 1979,
Lewis and Kaita9 first described linkage of Rd and RH
on chromosome 1 through linkage analysis and LOD
scores. This newfound linkage of Rd and RH raised the
possibility that the Rd antigen was part of the Scianna
blood group system.9 Spring demonstrated that anti-Rd
gave a specific positive immunoblotting reaction to a
broadly migrating component of approximate
apparent molecular weight (Mr) 60 to 68 kD in Rd+
RBC membranes under nonreducing conditions that
was not evident in Rd– RBC membranes.10 This
component was of a similar size to that defined by anti-
Sc1 in the same membrane preparations.10 Rd,
however, remained autonomous and was assigned to
the 700 series of low-incidence antigens by the ISBT.
After more than 20 years of researchers’ suggesting
the possibility that the Rd antigen belonged to the
Scianna blood group system, Rd was finally proved to
reside on the Scianna glycoprotein. This was achieved
through the sequencing of the gene encoding the
human erythrocyte membrane–associated protein
(ERMAP) in 2002 byWagner et al.11 The Rd antigen was
assigned to the Scianna blood group system and named
Sc4.12
During the preparation of this review, an exciting
discovery was made in the Scianna blood group
system. A high-prevalence antigen named STAR was
assigned into the blood group system and given the
ISBT number 01300512; it became the fifth recognized
antigen (Sc5) in the Scianna blood group system.
Properties of the Scianna Glycoprotein
Immunoblotting of RBC membranes under
nonreducing conditions using anti-Sc1 and anti-Sc2
demonstrated that the Sc1 and Sc2 antigens are located
on a RBC membrane glycoprotein with an approximate
apparent Mr in SDS-PAGE between 60 and 68 kD.
13 The
copy number of the Scianna antigens on RBCs has not
been determined.
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Testing by hemagglutination has shown that both
Sc1 and Sc2 are sensitive to treatment with pronase
and require intact disulphide bonds for full antigen
expression.13 The Sc2-active glycoprotein is
susceptible to endoglycosidase-F (Endo F) digestion,
which suggests the glycoprotein carries one or more
complex N-glycans that are necessary for the
expression of the Sc2 antigen.13 The Sc1-active
glycoprotein appears to be resistant to Endo F
digestion and does not require the presence of an N-
glycan for expression. The Scianna glycoprotein does
not have a substantial content of O-glycans and is not
attached to the membrane by a glycosylphospha-
tidylinositol (GPI)-linkage.13 Recently, given the
historical data of the Mr of the Scianna glycoprotein
and the chromosomal position of SC, a mutual
compatibility was determined between the SC
glycoprotein and ERMAP.11 Thus, the antigens
comprising the Scianna blood group system have been
determined to be expressed by ERMAP.11
ERMAP is an erythroid single-pass adhesion/
receptor transmembrane glycoprotein11,14,15 (Fig. 1).
The predicted protein is made up of 475 amino acids
and is a member of both the IgV and B30.2 domain
immunoglobulin superfamilies (IgSF).14,15 Human
ERMAP is homologous with murine ERMAP (73%
identity or 346 of 475 amino acids and 14%
conservative changes or 67 of 475 amino acids).15 The
extracellular domain contains one IgV fold that is
homologous with the butyrophilin family of milk
proteins, myelin/oligodendrocyte glycoprotein (MOG)
autoantigen, and avian blood group antigens.15 The
intracellular region contains a conserved B30.2 domain
that is encoded by a single large exon that is
homologous with one encoding a similar domain in a
diverse group of proteins including butyrophilin,pyrin,
and MID1 (midline-1 protein).15 ERMAP is highly
expressed in erythroid cells in the fetal liver and adult
bone marrow as well as in reticulocytes and circulating
erythroblasts in fetal cord blood.14 In one Northern
blot, ERMAP mRNA was also weakly detectable in
peripheral blood leukocytes, thymus, lymph nodes, and
spleen, but was not detectable in most other adult
tissues.15 A possible explanation for this finding was
variable erythroid cell contamination in the tissues
harvested for the RNA extraction.15 The exact
physiological functions of ERMAP and the possible
roles it may play in human disease pathogenesis still
remain to be determined.
Scianna Antigens
The Scianna blood group system comprises five
known, distinct antigens: Sc1 (Sm), Sc2 (Bua), Sc3, Sc4
(Rd), and Sc5 (STAR). Sc1 and Sc2 are an antithetical
pair of high- and low-prevalence antigens, respectively.
Sc3 and Sc5 are antigens of high prevalence. Sc4 (Rd)
is an antigen of low prevalence with no known
antithetical relationship to another Scianna antigen.
ISBT terminology and the various phenotypes with
prevalence of the Scianna system antigens are
summarized in Tables 1 and 2,16 respectively. The
susceptibility and resistance of the antigens in the
Scianna system to various enzymes and chemicals are
listed in Table 3.16,17
Fig. 1. ERMAP protein and Scianna polymorphisms. Figure is a
modification of that found in The Blood Group Antigen
FactsBook.16
Table 1. ISBT terminology for the Scianna blood group system




Sc4 (Rd) SC4 013004 700.015
Sc5 (STAR) SC5 013005
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Addition of STAR to Scianna
Skradski et al.18 first described an antibody found in
a Caucasian man, R.S., with an apparent Sc:1,–2
phenotype, that reacted with approximately 200 donor
RBC samples but not with his own, those from one
brother (whose RBCs also typed Sc:1,–2) nor two
examples of Sc:–1,–2 RBCs. Further findings were
detailed by Devine et al.,19 who described serologic
evidence that Sc:–1,–2,–3 RBCs lack multiple high-
prevalence antigens. The study by Devine et al. further
described the before-mentioned patient with the
Sc:1,–2 phenotype and two additional patients with
the same Sc:1,–2 phenotype whose sera contained
antibodies directed at a high-prevalence antigen. In
each case, the antibody was reactive with all RBCs
tested except the patient’s own and Sc:–1,–2,–3 RBCs.
The antibody present in each case was not mutually
compatible. The antigen recognized by the antibody
made by R.S. initially described by Skradski et al. in
1982 is now known as STAR.20
Scianna Alloantibodies and Their Clinical
Importance
Alloantibodies directed at Scianna antigens are rare,
and little is known about their clinical significance.
However,most of what is known about them is derived
from studies on Scianna autoantibodies and anti-Sc
associated with pregnancy and HDN. Survival studies
using radiolabeled RBCs have been published in only a
few studies on the known Scianna antibodies.
One study suggested that anti-Sc3 may be clinically
significant based on findings that used Cr51-tagged
Sc:1,–2 RBCs.6 Similarly, one of the Scianna-related
antibody cases (case #2) described by Devine et al.19
was reported to have been implicated in a delayed
hemolytic transfusion reaction, while another case
(case #1)19 demonstrated a good initial survival of Cr51-
labeled Sc3+ RBCs.
The first reported case of anti-Sc1 was described in
a woman (Mrs.N.S.) who was also highly immunized to
Rh D.1 She was multiparous and all pregnancies after
the first resulted in a fetus with HDN. However, in
these cases it was impossible to assess the clinical role
of anti-Sc1 in the HDN due to the presence of the anti-
D in her serum.
Another example of anti-Sc1 was described by
Kaye et al.21 In this case report, anti-Sc1 associated with
pregnancy was reported in a 28-year-old gravida-2
woman of Indian extraction. The anti-Sc1 was
determined to be solely of the IgG3 subclass. The
woman had no history of transfusion and no detectable
atypical antibodies in her serum during her first
pregnancy, and her RBCs typed Sc:–1,2. The woman
delivered a full-term infant. At birth, the cord RBCs
were positive (3+) in the DAT with anti-IgG (only).
Anti-Sc1 was eluted from the cord RBCs. This antibody
did not complicate her pregnancy and the newborn
was not determined to be suffering from moderate or
severe HDN. Neither the mother nor the infant
required any transfusion and at 2 months of age the
infant’s RBCs were negative in the DAT.
The first case of HDN due to anti-Sc2 was reported
by DeMarco et al.22 The mother gave birth to a full-term




Sc:–1,2 Very rare 0%
Sc:1,–2,4 Very rare Very rare
Sc:1,2,4 Very rare 0%
Sc:1,–2,–5 Very rare 0%
Sc:–1,–2,–3 (Null) Very rare 0%
*more common in Mennonites
Table 2 is a modification of that found in The Blood Group Antigen FactsBook.16
Table 3. Effect of enzymes and chemicals on intact RBC Scianna antigens
Antigen Ficin/papain Trypsin α-chymo-trypsin Pronase Sialidase DTT 200 mM/50 mM
Sc1 Resistant Resistant Resistant Weakened/sensitive* Resistant Sensitive/resistant
Sc2 Resistant Resistant Resistant Sensitive Resistant Sensitive/resistant
Sc3 Resistant Resistant Resistant Sensitive Resistant Sensitive/resistant
Sc4 Resistant Variable Variable Sensitive Resistant Sensitive/resistant
Sc5 Presumed resistant Presumed resistant Presumed resistant Presumed sensitive Presumed resistant Presumed sensitive/
resistant
*RBC membranes by immunoblotting
Sources for this information: The Blood Group Antigens FactsBook16 and Applied Blood Group Serology17
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infant. On Day 2 of life, the infant developed jaundice.
The DAT on the stored cord RBCs revealed a weak
positive reaction with anti-IgG. The DAT was performed
again on a peripheral blood sample at Day 2 and it was
2+ with anti-IgG. An eluate prepared from the infant’s
RBCs contained anti-Sc2. The infant had a Hct of 45% on
Day 2. Phototherapy was administered due to the
jaundice and the infant was discharged after Day 3. Ten
days later at a visit to the pediatrician, blood tests
revealed that the infant’s Hct had dropped to 22.6 %.
The infant was monitored for the next 5 days. On Day
20, the hematocrit had dropped to 17.3 % without
evidence of bleeding. The infant was hospitalized due
to pallor, tachypnea, and tachycardia because of the
severe immune hemolysis. The DAT on the infant’s
RBCs was 2+ with anti-IgG and anti-C3 reagents, and
testing revealed an LDH level of 437 U/L (twice the
upper limit of normal). The infant received 45 mL of
crossmatch-compatible RBCs and the posttransfusion
hematocrit increased to 27.8 %. The infant was
discharged the following day and remained stable
without anemia or the need of transfusion.
As previously mentioned,Rausen et al.8 reported on
five cases of anti-Rd (Sc4). In that report, anti-Rd caused
mild to moderate HDN with only one infant requiring
exchange transfusion. The production of the anti-Rd in
these cases seemed to be stimulated (only) by
pregnancy. However, Lundsgaard et al.23 reported on
two additional cases of anti-Rd. The first case was an
anti-Rd reported in a woman who was immunized by
transfusion. This patient’s RBCs were also positive in
the DAT. A heat elution was performed on her RBCs,
but the eluate reacted with all RBC samples tested
regardless of their Rd phenotype. The second case
reported was an anti-Rd found in a man who had never
previously been hospitalized or transfused. The DAT
on his RBCs was negative. In this case, it is believed
that this anti-Rd was “naturally occurring.” Before the
addition of Rd to the Scianna blood group system,there
were no cases of a “naturally occurring” Scianna
alloantibody reported.
There are no reported data on the clinical
importance of anti-STAR (Sc5). The characteristics and
clinical significance of the Scianna alloantibodies are
summarized in Table 4.16,17
Suppression of Sc Antigens and the
Production of Sc Autoantibodies
In 1979,Tregellas et al.24 described the first known
auto anti-Sc1. The antibody-maker’s RBCs were Sc:1,–2
with a weakly positive DAT due to bound IgG and C3d.
The most interesting finding in this case was that the
autoantibody produced was demonstrable in serum,
but not in plasma. The antibody was IgG3 and,because
it was detected in a healthy blood donor, it appeared
not to be causing any in vivo RBC destruction.
McDowell et al.25 described two cases of autoimmune
hemolytic anemia (AIHA) associated with auto anti-Sc1
due to transient suppression of Sc1. Similarly, Owen et
al.26 described a case of severe, acute AIHA in infancy
found in a West Indian girl that was associated with
auto anti-Sc1. The hemolysis was resistant to steroid
therapy, but was resolved following splenectomy and
two courses of high-dose IVIG given perioperatively.
This case was novel because it was the first report of
an auto anti-Sc1 that was detected by both serologic
techniques and immunoblotting as well as having been
the first instance of auto anti-Sc1 associated with
severe, acute AIHA in childhood.
Peloquin et al.27 described two cases of an apparent
auto anti-Sc3 in two patients with suppressed Sc1 and
Sc3 antigens. Both patients had an auto anti-Sc3–like
antibody in both their serum and their plasma. The first
case was a 64-year-old patient with lymphoma who had
severe anemia. The patient’s RBCs had a positive DAT
due to weakly bound IgG and strongly bound C3d. The
patient was transfused with five units of
incompatible RBCs without any apparent
adverse effect. The auto anti-Sc3
disappeared within 70 days of
transfusion, but suppression of Sc1 and
Sc3 antigens remained. The second case
was a 54-year-old patient with Hodgkin’s
disease and congestive heart failure who
had moderate anemia. The patient’s RBCs
had a positive DAT due to bound C3d
only. The patient was transfused with six
units of incompatible RBCs and the
Table 4. Characteristics of Scianna alloantibodies
Optimal Complement Immunoglobulin Transfusion
Antibody technique binding class reaction HDN
Anti-Sc1 IAT No IgG No Positive DAT 
only
Anti-Sc2 IAT No IgG No Mild
Anti-Sc3 IAT No IgG No Mild
Anti-Sc4 IAT No IgG No Mild
(Rd) to severe
Anti-Sc5 IAT Not known IgG None None
(STAR) reported reported
Sources for this information: The Blood Group Antigens FactsBook16 and Applied Blood Group Serology17
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antibody became slightly weaker. Follow-up studies
were not possible in this latter case. These studies
suggest that the formation of autoantibodies to Scianna
antigens represents transient antigen suppression with
concomitant antibody production.
Molecular Basis of Scianna 
Over the span of years, Lewis et al.9,28 showed
through linkage data analysis that SC and RH were
linked on chromosome 1p; however, they remained
distinct. Noades et al.29 provided independent
confirmation of Lewis et al’s claim of Rh linkage. The
genomic location of the SC locus is 1p3415,16 (Fig. 2).
ERMAP, the gene encoding the Sc glycoprotein, is
structured into 11 exons spanning 19 kbp of genomic
DNA (gDNA).11,15,16
The genetic basis of the SC polymorphisms was
determined by sequencing of ERMAP.11,20 The poly-
morphisms underlying the Scianna antigens (except
the Scnull phenotype) are based on single nucleotide
substitutions in ERMAP (Fig. 3).
At present, the reported molecular basis of the one
Scnull (Sc:–1,–2,–3) phenotype described resulted from a
2-bp deletion detected in exon 3 (307delGA). This
induced frameshift caused a nonfunctional, truncated
protein of 113 amino acids. Additionally, nucleotide
substitutions 54C>T and 76C>T detected in exon 2
caused a His26Tyr amino acid substitution at codon
26.11 There was no evidence for a second ERMAP allele,
which suggested homozygosity for the ERMAP (54C>T,
76C>T,307del2) allele.11 However, this group suggested
as an unlikely alternative that the ERMAP (54C>T,
76C>T, 307del2) allele could be in trans to a second,
Fig. 2. Genomic location of ERMAP locus and its proximity to RH on
chromosome 1. Figure is a modification of that found in The
Blood Group Antigen FactsBook.16 pter and qter denote the
termini of the chromosome.
Fig. 3. ERMAP gene and the nucleotide substitutions underlying the Scianna polymorphisms and Scnull phenotype. Figure is a modification of that found
in The Blood Group Antigen FactsBook.16
I M M U N O H E M A T O L O G Y, V O L U M E  2 1 , N U M B E R  2 , 2 0 0 5 75
Scianna blood group system
nonfunctional allele that possessed gross structural
changes that prevented amplification of exons 2 and 3.11
The nucleic and amino acid sequence data obtained by
Wagner et al.11 were deposited in EMBL/GenBank/DDBJ
under accession numbers AJ505027 to AJ505050.
Conclusion
The molecular basis of the Scianna antigens and the
Sc glycoprotein was unknown until it was shown that
they were carried on ERMAP, a glycoprotein of similar
size. Sequencing of ERMAP allowed the elucidation of
the molecular basis of the Scianna blood group system.
The polymorphisms underlying the Scianna antigens
are based on single nucleotide substitutions in ERMAP,
with the exception of the Scnull phenotype. The recent
identification of the STAR antigen during the
preparation of this review was only possible with this
gene sequencing data. As STAR was a serologic
curiosity buried in manuscript for more than 20 years,
the molecular basis of Scianna may now allow for
future elucidation of case studies that remain
unresolved and also assist in discovery of the new.
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